ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2462

A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis

Enming Su1, Pei-Suen Tsou1, Mark Warnock2, Natalya Subbotina1, Kris Mann1, Sirapa Vichaikul1, Xianying Xing1, Enze Xing1, Olesya Plazyo1, Rachael Wasikowski1, Lam C. Tsoi3, Mark Weinberg4, Cory D. Emal5, Dinesh Khanna1, John Varga1, Thomas H. Sisson1, Johann Gudjonsson1 and Daniel Lawrence2, 1University of Michigan, Ann Arbor, MI, 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4MDI, Ann Arbor, MI, 5EMU, Ann Arbor, MI

Meeting: ACR Convergence 2024

Keywords: clinical trial, Fibroblasts, Dermal, Mouse Models, Other, Scleroderma, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic sclerosis (SSc) is a complex and heterogeneous condition characterized by progressive fibrosis in multiple organs. Currently, there is no known cure for SSc, and treatment aims to manage symptoms, slow disease progression, and improve quality of life. Recent studies have implicated plasminogen activator inhibitor 1 (PAI-1, gene SERPINE1) in the pathogenesis of SSc, and PAI-1 is considered a prognostic biomarker for disease progression.

Methods: PAI-1 expression is evaluated in clinical dermal samples from SSc patients, using single-cell RNA-seq analyses.  Additionally, dermal fibroblasts collected from diffuse cutaneous (dc)SSc patients were evaluated for PAI-1 expression as well as changes in pro-fibrotic biomarkers after PAI-1 inhibition. Finally, a causal role for PAI-1 in fibrosis progression was examined in a preclinical model of SSc where bleomycin was administered subcutaneously via an osmotic pump for 7 days to induce systemic fibrosis followed by treatment for 21 days with the potent PAI-1 inhibitor MDI-2517.

Results: Single-cell RNA-seq analysis of skin biopsies from 18 healthy controls and 22 SSc patients revealed a marked overlap between genes involved in extracellular matrix remodeling associated biological processes and SERPINE1 expression in myofibroblasts from scleroderma skin samples. Treatment of dermal fibroblasts from SSc patients with the small molecule PAI-1 inhibitor MDI-2517 reduced the expression of the profibrotic markers ColA1 and ACTA2. To investigate the therapeutic potential of MDI-2517, we evaluated the efficacy of this drug in reducing both skin and lung fibrosis in a preclinical mouse model of SSc. Treatment with MDI-2517 significantly reduced fibrosis in both the skin and lungs, and was superior to treatment with either pirfenidone or mycophenolate mofetil (MMF). Additionally, MDI-2517 significantly reduced the expression of key profibrotic biomarkers and attenuated weight loss. Compared to another PAI-1 inhibitor, tiplaxtinin, previously shown to be effective in a model of SSc, MDI-2517 was found to have superior efficacy at a 10-fold lower dose.

Conclusion: These findings highlight the role of PAI-1 in the pathogenesis of SSc, and the potential of MDI-2517 for the treatment of SSc. Based on these promising preclinical studies and standard non-clinical toxicology and safety pharmacology studies a Phase 1 first in human clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MDI-2517 is currently underway. The results of the phase 1 study will inform the continued development of MDI-2517 for the potential treatment of SSc and interstitial lung disease, and will also support the potential evaluation of MDI-2517 in other chronic fibrotic and inflammatory diseases that are associated with excessive PAI-1 activity.


Disclosures: E. Su: MDI Therapeutics, 8; P. Tsou: None; M. Warnock: None; N. Subbotina: None; K. Mann: None; S. Vichaikul: None; X. Xing: None; E. Xing: None; O. Plazyo: None; R. Wasikowski: None; L. Tsoi: Janssen, 5; M. Weinberg: MDI Therapeutics, 2; C. Emal: MDI Therapeutics, 8; D. Khanna: AbbVie/Abbott, 2, Amgen, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Certa Therapeutics, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, MDI Therapeutics, 8, Merck/MSD, 2, Novartis, 2, Zura Bio, 2; J. Varga: None; T. Sisson: None; J. Gudjonsson: AbbVie/Abbott, 12, support, Boehringer-Ingelheim, 12, support, Bristol-Myers Squibb(BMS), 12, support, Eli Lilly, 12, support, Janssen, 12, support, Novartis, 12, support; D. Lawrence: MDI Therapeutics, 8.

To cite this abstract in AMA style:

Su E, Tsou P, Warnock M, Subbotina N, Mann K, Vichaikul S, Xing X, Xing E, Plazyo O, Wasikowski R, Tsoi L, Weinberg M, Emal C, Khanna D, Varga J, Sisson T, Gudjonsson J, Lawrence D. A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-potent-inhibitor-of-pai-1-mdi-2517-mitigates-disease-severity-in-preclinical-models-of-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-potent-inhibitor-of-pai-1-mdi-2517-mitigates-disease-severity-in-preclinical-models-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology